Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorclobutinamide
- Development stage
- Phase 1
- Lead developer
- Beijing Bolivikon Pharmaceutical Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chlorclobutinamide is a small molecule antiepileptic drug candidate developed by the Beijing Bolivikon Pharmaceutical Research Institute. It is a butyramide derivative currently being evaluated for the treatment of epilepsy. Clinical development has primarily taken place in China, including Phase 1 pharmacokinetic and safety studies (such as trial CTR20140139). The drug is designed to modulate neuronal excitability, potentially through the enhancement of GABAergic inhibitory neurotransmission or the stabilization of ion channels, although its precise molecular target remains to be fully characterized in public clinical literature.
- Other names
- 氯氯丁酰胺
Beyond the preview
Go deeper on chlorclobutinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorclobutinamide.